BioCryst to Report Fourth Quarter 2025 Financial Results on February 26
Rhea-AI Summary
BioCryst (Nasdaq: BCRX) will report fourth quarter 2025 financial results on Thursday, February 26, 2026. Management will host a conference call and webcast at 8:30 a.m. ET to discuss results and provide a corporate update.
Live domestic and international dial‑in numbers are provided, and a webcast replay will be available in the investors section of the company website.
Positive
- None.
Negative
- None.
News Market Reaction – BCRX
On the day this news was published, BCRX declined 2.80%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
BCRX fell 4.18% while several peers (AVDL, HROW, PAHC, AMPH) also showed smaller declines and BGM dropped sharply, but momentum scans did not flag a coordinated sector move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jan 23 | Acquisition completion | Positive | +0.6% | Closed Astria Therapeutics acquisition, adding Phase 3 HAE asset and leadership. |
| Jan 12 | Prelim revenue beat | Positive | -4.2% | Reported 2025 ORLADEYO net revenue of <b>$601M</b>, beating prior guidance range. |
| Jan 06 | Inducement equity grant | Neutral | +2.3% | Granted 18,300 RSUs to new hire under Nasdaq inducement equity plan. |
| Jan 06 | Conference presentation | Neutral | +2.3% | Announced presentation slot at 44th Annual J.P. Morgan Healthcare Conference. |
| Dec 12 | FDA approval | Positive | -0.1% | Received FDA approval for ORLADEYO oral pellets for HAE patients aged 2–<12. |
Recent history shows mixed reactions: some positive catalysts (acquisition, FDA approval, strong revenue) were followed by both gains and declines, suggesting news flow and price reactions have not been consistently aligned.
Over the past few months, BioCryst reported several major developments, including FDA approval of ORLADEYO oral pellets for HAE pediatric patients on Dec 12, 2025 and strong preliminary 2025 ORLADEYO revenue of $601 million with 37% year-over-year growth. The company also pursued strategic growth through the Astria acquisition completed on Jan 23, 2026. Smaller corporate updates, such as inducement grants and a J.P. Morgan conference appearance, rounded out the flow. Today’s earnings date announcement fits into this ongoing cadence of operational and strategic news.
Market Pulse Summary
This announcement sets the timetable for BioCryst’s detailed Q4 2025 and full-year discussion on February 26, 2026, with management hosting a call and webcast at 8:30 a.m. ET. It follows significant recent developments, including the Astria acquisition, preliminary ORLADEYO revenue of $601 million, and an FDA approval in pediatric HAE. Investors may focus on how these items flow into reported results, updated guidance, and any balance sheet commentary provided on the call.
AI-generated analysis. Not financial advice.
RESEARCH TRIANGLE PARK, N.C., Feb. 05, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its fourth quarter 2025 financial results on Thursday, February 26, 2026.
BioCryst management will host a conference call and webcast at 8:30 a.m. ET that day to discuss the financial results and provide a corporate update.
The live call may be accessed by dialing 1-844-481-2942 for domestic callers and 1-412-317-1866 for international callers. A live webcast and replay of the call will be available online in the investors section of the company website at www.biocryst.com.
About BioCryst Pharmaceuticals
BioCryst is a global biotechnology company focused on developing and commercializing medicines for hereditary angioedema (“HAE”) and other rare diseases, driven by its deep commitment to improving the lives of people living with these conditions. BioCryst has commercialized ORLADEYO® (berotralstat), the first oral, once-daily plasma kallikrein inhibitor, and is advancing a pipeline of potential first-in-class or best-in-class oral small-molecule and injectable protein therapeutics for a range of rare diseases. For more information, please visit www.biocryst.com or follow us on LinkedIn.
BCRXW
Contact:
Investors:
investorrelations@biocryst.com
Media:
media@biocryst.com
FAQ
When will BioCryst (BCRX) report fourth quarter 2025 financial results?
What time is the BioCryst (BCRX) Q4 2025 earnings call and webcast?
How can investors access the BioCryst (BCRX) February 26 webcast and replay?
What dial‑in numbers should domestic and international investors use for the BioCryst (BCRX) call?
Will BioCryst (BCRX) management provide a corporate update during the Q4 2025 call?
